Introduction {#s1}
============

Research into the genetics of breast tumors has yielded comprehensive portraits of the somatic alterations acquired during the evolution of breast cancer genomes. Catalogues of recurrent driver alterations have been identified using an array of technologies ([@bib53]; [@bib1]; [@bib16]; [@bib52]; [@bib27]; [@bib5]; [@bib13]; [@bib50]; [@bib17]; [@bib43]). This information has been instrumental in furthering our understanding of the basic biology that underlies breast cancer development and has led to the development of diagnostic and prognostic tests and more importantly, the development of efficacious targeted therapies ([@bib20]). While the adoption of therapeutic strategies targeting somatic cancer alterations and the pathways they control has had a profound impact on the treatment of breast cancer ([@bib3]), disease relapse and therapeutic resistance remain important challenges ([@bib34]; [@bib36]). Recent research into these phenomena has implicated genetic heterogeneity (i.e. sub-clonal variation or intra-tumoral heterogeneity) as a common mechanism to explain recurrence and treatment failure ([@bib54]; [@bib15]; [@bib39]). However our knowledge of intra-tumoral genetic heterogeneity is limited and thus advancing it is instrumental in combating cancer.

CNAs are an important class of somatic mutations that are acquired during the evolution of breast cancer genomes ([@bib20]). Studies exploring the landscape of CNAs have considerably advanced our knowledge of breast cancer biology, with translational efforts leading to advances in the clinic. Most notably, the amplification of the ERBB2 (HER2) oncogene defines a biological subtype of breast cancers and targeting this CNA has led to the development of a multitude of efficacious therapeutic agents that have dramatically increased the survival of HER2+ patients ([@bib4]). Additionally, numerous studies have demonstrated the utility of copy number information in the prognostic stratification of breast tumors ([@bib49]; [@bib19]) and studies of the genes targeted by this class of somatic mutations have substantially advanced our understanding of breast cancer biology ([@bib29]; [@bib12]). However, our knowledge of CNA intra-tumoral genetic heterogeneity is limited and given the importance of this class of somatic alterations warrants further investigation.

Single-cell DNA sequencing methods have recently emerged as powerful tools for the study of intra-tumoral heterogeneity with recent applications in breast ([@bib41]; [@bib24]) and other tumors ([@bib26]; [@bib11]; [@bib10]) revealing novel cancer genetics and biology. Here, we present a comprehensive analysis of CNAs in breast cancer based on the sequencing of thousands of single-cell genomes across a cohort of breast tumors. Our results offer in-depth views of the magnitude of intra-tumoral CNA heterogeneity present in breast cancer genomes, reveal novel and important observations that have been missed by earlier bulk studies, highlight the unique nature of the data and its ability to retrieve novel knowledge, and provide an important foundation for the future exploration of intra-tumoral genetic heterogeneity of this important class of somatic mutations.

Results {#s2}
=======

Samples, annotations and sequencing {#s2-1}
-----------------------------------

Samples from sixteen patients were selected from a cohort population enrolled in two phase II open-label clinical trials conducted by the Brown University Oncology Group (BrUOG). Two pre-treatment, freshly frozen biopsies per patient were obtained. Two blood samples from normal healthy individuals were also obtained and processed (discussed below -- Methods). For the tumor samples, one biopsy was subject to bulk DNA and RNA isolation for transcriptome sequencing and copy number profiling by sparse sequencing. The second biopsy was subjected to single-cell copy number analysis as described previously ([@bib6]; [@bib7]). In brief, tissue was processed to obtain a suspension of DAPI stained single-nuclei. Nuclei were subsequently flow sorted by ploidy (measured by DNA-content) for single-nucleus deposition, genome amplification and sequencing. For samples with multi-modal ploidy distributions (i.e. diploid and polyploid populations) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), single-nuclei were sorted and sequenced from each distribution. A mean of 116 single-nuclei per tumor sample were sequenced in multiplex fashion for a total of 2086 single-cell genomes. For each nucleus, we targeted a sequencing depth of roughly 2 million reads, sufficient to call large copy number events (\>1 MB) as well as focal events such as amplifications and deletions at a resolution of roughly 300kbs . Selected patient samples were representative of various biological and clinical variables such as PAM50 subtype, ploidy, and ER/PR/HER2 status as well as other parameters such as age and tumor size ([Figure 1---figure supplement 1B--D](#fig1s1){ref-type="fig"}).

CNAs and genetic heterogeneity of stromal, non-cancer cells {#s2-2}
-----------------------------------------------------------

Nuclei processed from the diploid (2N) distribution of sorted samples could either represent cancer cells or normal cells present in the tumor mass (i.e. normal epithelia, fibroblasts, and/or immune cells). When sequencing 2N nuclei of patient samples, we obtain copy number neutral, 'flat' genome profiles representative of non-cancer, stromal cells ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). Intriguingly, we observed recurrent focal homozygous deletions on chromosomes 14 and 7, in otherwise diploid genomes ([Figure 1A](#fig1){ref-type="fig"}). Further inspection localized the deletions to T-cell receptor alpha (TCRa) and beta (TCRb) loci ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). These deletions are the result of T-cell maturation and generated via the process of V-D-J recombination. Similarly, we observed focal homozygous deletions at the heavy and light Immunoglobulin loci (IGH and IGL) on chromosomes 14 and 22, respectively, denoting B-cells ([Figure 1B](#fig1){ref-type="fig"}). Thus, using single-nuclei copy number sequencing we can detect T- and B-cells present within the tumor mass. To gauge the sensitivity of T- and B-cell detection, we retrieved highly purified CD4+/CD8+ T-cells and CD27+/CD13+ B-cells and performed single-nuclei copy number analysis on approximately 96 nuclei for both samples with the expectation that all single-nuclei should carry their respective deletions. Deletion analysis led to a calculated detection sensitivity of \~80% and 50% for T- and B-cells, respectively ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). This allowed the quantification of T- and B-cells in the tumor mass in our samples and led to the detection of T-cells (in varying proportions) in almost all patient samples, with B-cell infiltration limited to a subset of tumors, ([Figure 1C](#fig1){ref-type="fig"}) consistent with previous studies ([@bib48]).

![Genetic heterogeneity of immune cells and pseudo-diploid cells in breast cancer biopsies.\
(**A**) Genome-wide copy number view of representative single-cell T-cell genomes illustrating T-Cell Receptor alpha (TCRa) and beta (TCRb) deletions. (**B**) Genome-wide copy number view of representative single-cell B-cell genomes illustrating light (IGL) and heavy (IGH) immunoglobulin deletions. (**C**) Bar plot quantification of T-cells, B-cells, pseudo-diploid cells and other non-tumor cells identified in profiled tumor biopsies. (**D**) Zoomed in views of TCRa deletion breakpoints in single T-cells found in tumors biopsies (P15 and P9), blood purified CD8+/4+ T-cells, and single-leukemic cells derived from a T-cell leukemia. (**E**) Representative genome-wide copy number plot of a T-cell exhibiting X-chromosome loss. Insert -- bar plot quantification of X-loss T-cells in ER+ and ER- tumors. Asterisk denotes statistical significance based on chi-square test (p-value=0.0047). (**F**) Left panel: Frequency plot of CNAs identified in a panel of 200 breast cancer genomes. Highly recurrent alterations, such as 1q gain and 16 p loss are noted. Right Panel: Representative copy number plots of pseudo-diploid single-cell genomes illustrating the occurrence of recurrent breast cancer CNAs in these cells.\
Figure 1---source data 1.Patient sample associated metadata.](elife-51480-fig1){#fig1}

Given the importance of T-cells in emerging immunotherapies ([@bib51]), we performed more detailed analysis on the identified T-cells and queried whether they represent clonally expanded T-cells that have infiltrated the tumor mass, or TCRa unique, non-clonal T-cells. To gauge the specificity in detecting genetically unique T-cells using single-cell sequencing we examined the pattern of breakpoints resulting from TCRa deletions. In the purified CD4+/CD8+ T-cell nuclei (n = 95), deletion breakpoints were found distributed over 14 genomic bins and in the majority of T-cells were not shared, suggesting unique TCRa recombination events ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}). Extending this breakpoint analysis to T-cells identified in patient biopsies, we found that within a given tumor none of the T-cells shared identical breakpoints, similarly suggesting that the identified T-cells were non-clonally derived and genetically distinct. This is in contrast to the breakpoints observed in nuclei derived from a T-cell leukemia which were recurrent and positionally identical across different single nuclei ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). To quantitatively corroborate these observations, we devised a breakpoint distance metric and applied it to the abovementioned T-cell groupings (Methods). Indeed, we find lower breakpoint pairwise-distance values in the single-nuclei derived from the T-cell leukemia compared to both CD8+/CD4+ T-cells and T-cells found in breast cancer biopsies ([Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}). All the T-cell leukemia nuclei in this analysis shared identical breakpoints, p-value\<10^−6^, in contrast to T-cells found in tumor biopsies. In addition to the heterogeneity of the TCRa deletion breakpoints in T-cells, we observed large karyotypic abnormalities affecting some T-cell genomes ([Figure 1---figure supplement 2G](#fig1s2){ref-type="fig"}). These karyotypic abnormalities were represented overwhelmingly by a loss of an entire copy of the X chromosome ([Figure 1E](#fig1){ref-type="fig"}) consistent with previous karyotyping studies of proliferating lymphocytes ([@bib44]). These X-loss T-cells, when found in the same patient sample, were genetically distinct at their respective TCRa locus as judged by the deletion breakpoints as well as the above mentioned breakpoint-distance metric ([Figure 1---figure supplement 2E and F](#fig1s2){ref-type="fig"}). Interestingly, T-cells displaying X-loss were found more frequently in estrogen receptor negative (ER-) compared to estrogen receptor positive (ER+) tumors (p-value=0.0047) ([Figure 1E](#fig1){ref-type="fig"}, insert). Given that BRCA1 has been shown experimentally to be associated with the process of X-inactivation ([@bib28]) and that BRCA1-mutant tumors are mostly ER- tumors, this association is intriguing.

Additionally, we and others have reported the detection of individual, aneuploid nuclei that carry non-clonal, genetically heterogeneous CNAs termed pseudo-diploids ([@bib41]; [@bib22]). Initially identified in two triple negative primary tumors and not their matching metastasis ([@bib41]), here, we extend their observation to tumors from all four PAM50 subtypes studied (i.e. LumA, LumB, HER2+, and Basal) ([Figure 1c](#fig1){ref-type="fig"}). Interestingly, we find that some carry prototypical breast cancer CNAs such as gain of 1q and loss of 16 p ([Figure 1F](#fig1){ref-type="fig"} -- right panel). The pseudo-diploids observed in our cohort however do not appear to be precursors to the clonal cancer cells constituting the tumor mass as they do not share their respective CNAs ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). We interpret the observation of these nuclei as a manifestation of the inherent genomic instability present in normal breast epithelial cells of cancer patients. Further analyses, across a larger number of single pseudo-diploid nuclei while also factoring somatic single-nucleotide variant (SNV) information, are required to definitively prove this.

Thus, using single-cell sequencing we were able to detect immune cells present within the tumor mass and infer their genetic heterogeneity as well as extend the identification of pseudo-diploids to all PAM50 breast cancer subtypes and observe the occurrence of cancer associated CNAs in these cells.

Genetic heterogeneity of large copy number alterations in cancer cells and the importance of dosage {#s2-3}
---------------------------------------------------------------------------------------------------

We then proceeded to analyze the genetic heterogeneity of large-scale CNAs present in sequenced single cancer nuclei. These events include CNAs larger than 3 MB as well as whole chromosome or arm level events. As a way of illustrating the data, we plot all single-nuclei copy number profiles from a given patient on the same graph. Doing so for tumor P5 (LumA), one can visually distinguish clonal from sub-clonal alterations by observing either one or multiple copy number states at any given genomic position, respectively ([Figure 2A](#fig2){ref-type="fig"}). For example, losses of 8 p and 18 p (recurrent CNAs in breast cancers) are found at one copy number state and are thus clonal events ([Figure 2A](#fig2){ref-type="fig"} -- red arrows). Alternatively, gains at 1q and 8q (also recurrent breast cancer CNAs) as well as losses on chromosomes 13 and X are found to be sub-clonal ([Figure 2A](#fig2){ref-type="fig"} -- blue arrows). For P5, computing the fraction of the genome found to be clonal/sub-clonal using a stringent threshold (minimum 10% of cells showing sub-clonality -- Materials and methods), we find P5 to be sub-clonal in over half of its genome (56% sub-clonal) ([Figure 2A](#fig2){ref-type="fig"} - top bar). Extending this analysis to all tumors, we find a wide range of fractional sub-clonal values with tumors showing: (1) significant (sub-clonal at \~\>40% genome -- Ex: P5, P22, and P59), (2) moderate (5%--20% subclonal\-- Ex: P14, P58, and P31) or (3) low levels of heterogeneity (subclonal at \<5% of genome -- Ex: P16, P41, P1) ([Figure 2B](#fig2){ref-type="fig"}). Representative examples of significant, moderate, and low level CNA heterogeneity samples, as illustrated for P5, are provided ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![Copy number heterogeneity impacts a significant proportion of breast cancer genomes and occurs at regions in the genome that are biologically and clinically important.\
(**A**) Schematic illustration of CNA heterogeneity in tumor P5. Single-cell genomes (n = 131) are plotted on the same copy number diagram. Heterogeneous/sub-clonal regions can be identified by the presence of multiple copy number states (ex: 1q and chromosome 13). Red arrows point to representative clonal alterations. Blue arrows point to representative sub-clonal alterations. (**B**) Quantification of copy number heterogeneity as fraction (%) of the genome found to be sub-clonal across all sequenced biopsies. (**C--H**) Representative chromosome wide views of identified sub-clonal CNAs affecting: regions recurrently altered in breast cancer genomes by CNAs (**C**), regions containing genes of therapeutic relevance (**D**), regions containing genes known to be affected by somatic SNVs (**E**), regions with experimental evidence of involvement in breast cancer metastasis (**F**), regions found at three or more different copy number states (**G**). Gray vertical bars denote the location of genes or CNAs. (**H**) Distant relapse-free survival curves for cases with 1q and 8q gains that are ER+ and HER2- (n = 428). Cases are stratified based on their level of 1q or 8q gain (low vs. high).\
Figure 2---source data 1.Inferred integer copy number values of all single cancer nuclei sequenced for all patients.](elife-51480-fig2){#fig2}

Importantly, regions found to be sub-clonal in tumor samples included regions: (1) known to be recurrently altered by CNAs (ex: 8 p and 13q), (2) harboring genes encoding therapeutic targets such as ESR1, CYP19A ([@bib25]), CDK6 ([@bib55]), and PD-L1 ([@bib40]), (3) harboring genes known to be recurrently mutated by single nucleotide variants (SNVs) such as PIK3R1, PDGFRA, and RUNX1 ([@bib13]; [@bib43]), and (4) harboring genes experimentally shown to be involved in metastasis ([@bib57]; [@bib59]; [@bib46]; [Figure 2C](#fig2){ref-type="fig"} - F and [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). DNA-FISH was used to validate a selected subset of these alterations ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Importantly, for some of the alterations, we find that the sub-clonal CNAs exist at three or more distinct copy number states in different single cells, for example, 8q gains in P5 (LumA) and P22 (Basal) ([Figure 2G](#fig2){ref-type="fig"}). This may have an effect on the level of expression/dosage of genes encoded on those chromosomes and thus may affect phenotypic heterogeneity. Reasoning that the increase of dosage of genes at 8q and/or 1q might be associated with advanced disease and hence bad prognosis, we devised an analysis approach to measure the relative dosage of these events in bulk copy number datasets and test their association with patient survival in a large, carefully annotated breast cancer dataset; METABRIC (20) (Methods). Indeed, we find that 1q/8q high tumors in ER+/HER2- patients (regardless of ploidy status of the tumor genome) are associated with worst distant relapse free survival ([Figure 2H](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Further, among the newly discovered breast cancer subgroups (IntClust, IC) groups, we find that 1q/8q high tumors are enriched in the IC9 subgroup which is associated with high-risk of late distant relapse ([@bib47]; [Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}).

Together, these data show that heterogeneity of large copy number events can: (1) affect a large proportion of the genome in any given tumor, (2) exist at multiple levels (ex: dosage - three or more copy number states in the same tumor), and (3) that this heterogeneity can affect regions of the genome that are important for treatment or disease relapse.

Multiple forms of genetic heterogeneity of focal chromosomal amplicons {#s2-4}
----------------------------------------------------------------------

Focal amplifications and deletions comprise another important class of CNAs. Prototypical driver amplifications containing ERBB2, CCND1, MYC, and CCNE1, as well as less commonly identified amplifications such as PPM1D and MDM2, were identified in our patient cohort and in some cases were clonal (i.e. identified in all single-nuclei sequenced) ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). However, as seen with larger CNAs, many tumors displayed chromosome amplifications genetic heterogeneity. For example in tumor P22 (basal), three focal amplicons encompassing the VEGFA, MYC and CCNE1 loci were found in varying proportions and in certain instances (VEGFA and CCNE1) in a mutually exclusive manner in sequenced single-nuclei (p-value=0.003 -- Fisher's Exact Test). A sub-population lacking any of the amplicons, but having lost an additional copy of the RB1 gene via a focal deletion was also identified ([Figure 3B and C](#fig3){ref-type="fig"} and [Figure 3](#fig3){ref-type="fig"} -- figure supplement B-D). Interestingly, the amplifications segregate with genetically distinct, geographically resolved tumor sub-populations ([Figure 3---figure supplement 1D and E](#fig3s1){ref-type="fig"}). Thus, P22 amplifications are somatically mosaic. Other examples of amplicon mosaicism include P5 (LumA) where an amplification targeting GATA6 was found only in a sub-population of cancer cells and P59 (Basal), where amplifications on multiple chromosomes (chromosomes 3, 5, 6 and 18) targeting important genes such as LOX ([@bib18]) and PRDM1 ([@bib43]) where found in the majority of cells but absent in others ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). In total, 6 out of the 16 (37%) tumors analyzed displayed amplicon mosaicism in the form of presence/absence of one or more amplicons in different subpopulations of cancer cells.

![Different forms of genetic heterogeneity in chromosomal amplifications.\
(**A**) Representative zoom-in chromosome views of clonal prototypical breast cancer amplicons such as ERBB2 and CCND1 identified in patient samples. (**B**) Genome-wide copy number profiles of representative (n = 4) single-cell genomes illustrating heterogeneous amplifications in tumor P22. Profiles are annotated with distinguishing amplicons. A representative profile of a single nucleus with no amplifications, but deleted for the RB1 gene, is also noted. (**C**) Heatmap illustration of P22 amplicon copy number heterogeneity and the mutually exclusive nature of the CCNE1 and VEGFA amplicons - statistical significance based on Fisher's Exact Test (p-value=0.0032, Odds ratio = 0, 95% confidence interval 0--0.44). Single-nuclei are ordered according to hierarchal clustering as illustrated in [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}. Color key is according to increasing copy number states. (**D**) Genome-wide copy number profiles of representative single-cell genomes illustrating heterogeneous amplifications in tumor P6. Profiles with distinguishing amplifications are annotated on the figure. (**E**) DNA-FISH validation of somatic mosaicism of the SKIL and MYC amplicons in tumor P6. DNA-FISH data also illustrate the geographic demarcation of the amplification in the field of view. (**F**) Zoom-in-views of the SKIL and MYC amplicons in representative single-cells illustrating the heterogeneity in the level of chromosomal amplification in tumor P6. (**G**) DNA-FISH validation of low level/high-level amplification of SKIL and MYC loci inferred based on fluorescence signal intensity.](elife-51480-fig3){#fig3}

Presence or absence of an amplicon in single cells was not the only form of variation we observed in chromosomal amplifications. Another form of variation observed came in the form of the level (or dosage) of amplification. An example is P6 (HER2+) where different spatially resolved sub-populations were identified carrying either: (1) only ERBB2 amplification, (2) ERBB2 and SKIL amplifications, or (3) ERBB2, SKIL, and MYC amplifications ([Figure 3D and E](#fig3){ref-type="fig"}). Importantly, for the SKIL and MYC amplicons, different single-nuclei were found to have varying levels/dosage of amplification. Where in some single-nuclei, SKIL and MYC levels reached over 60 copies, in others the level of amplification was less pronounced. For the MYC locus for example certain subpopulations contained MYC amplifications at less than 30 copies ([Figure 3F](#fig3){ref-type="fig"}). This was confirmed using DNA-FISH analysis based on fluorescence signal intensity ([Figure 3G](#fig3){ref-type="fig"}). This heterogeneity in amplicon level/dosage was also observed for the ERBB2 locus in another one of the six HER2 amplified tumors we analyzed ([Figure 3---figure supplement 2B and C](#fig3s2){ref-type="fig"}). Thus, chromosomal amplicons can exist at different levels within different single cells in a tumor mass.

We also observed homozygous deletions affecting known breast cancer genes such as MLLT4, MAP2K2, and NCoR1, among others ([@bib13]; [@bib43]; [Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). However, we did not observe heterogeneity in this class of CNAs. We cannot rule out genetic heterogeneity of this form of variation since homozygous deletions are generally smaller in size than chromosomal amplifications and at the resolution of our analysis may have gone undetected. Nonetheless, our results illustrate varied forms of genetic heterogeneity in chromosomal amplicons affecting important breast cancer genes in a significant proportion of breast tumors. These observations are particularly important given that driver cancer genes commonly found in amplicons are generally perceived to be good targets for drug development ([@bib13]), have been found to be associated with metastatic breast cancer ([@bib9]), and because sub-clonality of amplifications is difficult to infer from bulk sequence data (especially targeted sequencing) given its quantitative nature, as opposed to qualitative nature of SNVs.

Single-cell genome sequencing and multi-region sampling yield complementary information {#s2-5}
---------------------------------------------------------------------------------------

Previous studies utilizing multi-region sequencing to investigate somatic SNVs in breast and lung cancer have shown that a significant proportion of the variation that is found between different spatially resolved biopsies can be detected at the sub-clonal level in one of the biopsies with deeper sequencing ([@bib21]; [@bib62]; [@bib61]). This has not been investigated in a genome-wide, unbiased manner for CNAs. For 9 of the 16 tumors analyzed, we were able to sequence and compare bulk DNA from two spatially resolved biopsies for CNAs. In concordance with previous studies, we find substantial differences in CNAs between biopsies ([@bib61]). Interestingly however, we find that much of the variation observed between the two biopsies can also be observed as sub-clonal variation in the single-cell data ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). For example, in tumor P22 (Basal), differences on chromosomes 8, 12, 15 and X were observed between the two bulk profiles but were also observed sub-clonally at the single-cell level ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). Of 54 alterations differentially found in the two analyzed biopsies from the nine patients, 35 (65%) were identified in the data from single nuclei. This was observed for broad copy number events as well as focal amplifications, for example CCNE1 and GATA3 ([Figure 4B](#fig4){ref-type="fig"}). Importantly, additional heterogeneous CNAs were detected only in the single-cell data and not in the bulk comparisons, for example variation on chromosome 1q and 1 p in P22 as well as alterations on 1q and chromosome four in P5, with the converse also being true ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Thus, in our cohort, a substantial proportion (but not all) of variation in CNAs between spatially resolved biopsies is detected at the single-cell level with higher resolution analysis and some variation is only observed at the single-cell level or via multi-region sequencing.

![A substantial amount of copy number variation observed between spatially resolved biopsies identified in bulk sequencing data is captured at the single-cell level in one of the biopsies.\
(**A**) Genome-wide copy number view of bulk copy number profiles from two different geographic biopsies (blue -- biopsy analyzed at bulk and single cell level, red -- biopsy analyzed only in bulk) from tumor P5 (top panel) and tumor P22 (bottom panel). Gray shading denotes variation identified at bulk level between the spatially resolved biopsies and captured in single-cell data. Yellow shading indicates variation not seen in single-cell data but found in the bulk comparison. Lavender shading indicates variation observed only at the single-cell level. (**B**) Chromosomal view of representative examples of spatial variation of chromosomal amplicons found heterogeneously at bulk and single-cell level. Top panel indicates % of single-cells with the respective chromosomal amplification in single-cell data.](elife-51480-fig4){#fig4}

CNA heterogeneity is associated with genetic, molecular, and clinical classifications {#s2-6}
-------------------------------------------------------------------------------------

To associate CNA heterogeneity with molecular and clinical parameters we utilized two metrics from the single-cell data, applying stringent thresholds (Methods). The first metric is the fraction of the genome found to be sub-clonal. The second metric is the number of recurrent, sub-clonal breakpoints. We chose four discrete variables for association analysis: PAM50 subtype annotation and ploidy status (biological parameters) and HER2 and estrogen receptor status (clinical parameters). Plotting the data in bar graph format with tumors rank ordered according to increasing levels of heterogeneity while applying Wilcoxon rank order testing for associations ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}) reveals several points. (1) Tumor samples of different PAM50 cancer subtypes display variable levels of CNA heterogeneity (i.e: inter-tumor CNA heterogeneity). For example, both P9 and P16 belong to the HER2+ subtype but differ markedly in their CNA heterogeneity profiles. Similarly, both P5 and P1 belong to the LumA subtype but display notable differences in CNA heterogeneity. Thus, for any given subtype, there appears to be a range in terms of CNA heterogeneity in the analyzed samples. We cannot associate or rule out an association between heterogeneity and any particular subtype due to the size of our cohort. Increasing sample sizes as well as analyzing multiple biopsies per sample in future studies will be required to delineate this. (2) Polyploid tumors are significantly more likely to be heterogeneous on the copy number level and this relationship is unrelated to the total number of clonal alterations found in each tumor. (3) As a group ER- tumors are significantly more heterogeneous on the copy number level than ER+ tumors. Thus copy number heterogeneity is variable within breast cancer tumors of the same subtype and is associated with tumor polyploidy and ER- disease. There is one exceptional outlier, an ER+/LumA (P5) with extensive copy number and clonal heterogeneity. Interestingly, unlike most ER+ tumors, P5 is mutated for the TP53 gene ([Figure 5B](#fig5){ref-type="fig"}), as are the majority of ER- tumors.

![Copy number heterogeneity is associated with biological and clinical parameters and tumors can be classified according to clonal composition.\
(**A**) Bar plot with rank order illustrating CNA heterogeneity as measured by fraction (%) of the genome found to be sub-clonal. Each tumor is denoted at the top of each bar with values of fraction (%) genome sub-clonal also annotated. Categories for association analyses are depicted in panel below. Asterisks denote categories with statistically significant associations based on Wilcoxon rank order tests (p-value=0.0229 and 0.0164 for ER- and polyploidy categories respectively). p-values were rounded and annotated in the figure panel. (**B**) A representative illustration of a Sanger sequencing trace of DNA from a single normal and single cancer cell from tumor P5, an ER+ tumor. Traces illustrate a G to A transition at position 7578500 of chromosome 17 resulting in a non-sense mutation in the TP53 gene. (**C**) Correlation analysis between fraction (%) of genome sub-clonal and the log of the tumor size (cm2) as measured by MRI. Pearson's rank correlation p-value=0.01912. Log of the size was used given the assumption of exponential tumor growth. P5, an ER+, TP53 mutant outlier is excluded from the analysis. (**D**) Representative MRI images of two patient tumors analyzed in this study illustrating the inverse correlation of tumor size and fraction of genome sub-clonal in ER+ tumors. Red colored ellipses denote tumor positions. (**E**) Heatmap illustration of three representative tumors displaying different clonal composition patterns. Patterns are: homogenous (P16), heterogeneous with a dominant clone (P14), and heterogeneous without a dominant clone (P5). Top bar denotes tumor identity with bottom bar depicting sub-clones. Heatmap color scheme is provided to the right of the heatmap. (**F**) Quantification and bar plot illustration of clonal composition as explained in E.](elife-51480-fig5){#fig5}

We also attempted to associate copy number heterogeneity across all samples with continuous variables such as patient age and tumor size and found no significant relationships ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). However, when restricting the analysis to ER+ tumors (and excluding the ER+/TP53 mutated case) we find a relationship where tumor size and CNA heterogeneity are inversely correlated (p-value=0.02793). The largest four tumors (measuring at more than 10 cm2) display the least amount of CNA heterogeneity ([Figure 5C and D](#fig5){ref-type="fig"}). This could be explained by the expansion and clonal sweep of a dominant clone in these tumors that is then captured when biopsying a geographically restricted region of a large tumor mass.

Lastly, we examined the clonal composition of cancer cells from analyzed tumor samples (i.e. \# of genetically distinct clones in a given sample and their relative frequencies) and find that tumor samples in general conform to three different clonal classes: (1) homogenous tumors where only a single clone is observed, found only in ER+ tumors; (2) heterogeneous tumors where multiple clones exist but with one clone dominant over others (i.e. dominant \>50%), a pattern found throughout the cohort subtypes; and (3) heterogeneous tumors where many clones are found at varying frequencies with none of them being dominant, mainly in ER- tumors ([Figure 5E and F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

Discussion {#s3}
==========

We provide a comprehensive analysis of breast cancer copy number alterations at the single cell level, and in the process, make many novel observations regarding the genetic heterogeneity of breast tumors. First, we observe an association between ER- tumors and T-cells exhibiting X-chromosome loss. This observation is at present of unclear clinical significance, but nevertheless might be a useful marker for this subtype of disease. Second, we observe pseudo-diploid single cells in the majority of our studied tumors, across different PAM50 subtypes, providing further evidence for the existence of such cells in breast cancer tissue. This, coupled with the observation of cancer-specific alterations (e.g. 1q gain and 16q loss) in these cells raises the question of whether these cells are a manifestation of the intrinsic genomic instability of the mammary epithelial cells of breast cancer patients and whether their detection might be useful in early stage risk assessment. Third, we observe profound genetic heterogeneity in CNAs affecting genes and regions with known biological relevance in breast cancer, such as genes associated with metastasis and therapeutic response. Thus, many cancer phenotypes might result from the selection for sub-clonal CNAs. Fourth, we find that CNA heterogeneity is not binary (i.e. sub-clonal or clonal). CNAs can be found at different copy numbers in different populations of cells and that this, in the case of 1q/8q gains is associated with clinical outcome, likely a consequence of dosage dependent biology. Fifth, the observation of mosaicism in recurrent driver amplicons in a significant proportion of tumors has clinical implications given that driver amplicon genes are often targets for drug development (e.g., ERBB2, MET, and EGFR) and have been proposed to be good targets for drug development in breast cancer ([@bib13]). Further, we find additional layers of heterogeneity in this class of CNAs: the presence or absence of an amplicon and variation in the level/dosage of amplification, which might be the result of extra-chromosomal amplicon instability ([@bib56]). This is of importance given that recent studies have provided evidence for a role of variation in gene dosage in therapeutic resistance to targeted therapy ([@bib60]). Sixth, the single-cell data show that a significant proportion, but not all, of the heterogeneity in CNAs found differentially between two spatially resolved biopsy samples is also captured at the single-cell level in one of the biopsies. Importantly, some variation is captured only in the single-cell data and not in the bulk comparisons. This provides a rationale for performing both spatial sampling of tumors and deep analysis of biopsy material for precision medicine applications ([@bib61]). Seventh, we see somewhat of an inverse correlation between tumor size and CNA heterogeneity in ER+ tumors, many of which present as a single large clone. Thus, for such large ER+ tumors, extensive spatial multi-region sampling might be necessary to capture a true picture of a tumor's genetic heterogeneity. Eight, the association of CNA heterogeneity with parameters such as polyploidy and ER- status provides an indirect association of heterogeneity with clinical outcome since both parameters have been shown to associate with a worse prognosis ([@bib14]; [@bib45]). Ninth, we observe that some tumors exhibit a multitude of sub-clones with no single sub-clone being dominant (largely observed in ER- tumors). This raises questions regarding the importance of clonal cooperation in the growth and evolution of breast tumors, an area for which experimental evidence has recently emerged ([@bib38]). All of the above mentioned findings provide novel observations upon which more focused investigations can be based (ex: X-loss in ER- tumors and pseudo-diploid cells) as well as a solid foundation for future, more expansive studies of CNA heterogeneity in breast, as well as other cancers.

Importantly, in contrast to bulk sequencing where elegant studies have used deep sequencing information to enable phasing and inference of genetic heterogeneity and clonality ([@bib50]; [@bib42]), our study highlights the power inherent in single-cell genomic investigations for the direct observation and quantification of genetic heterogeneity. Most of the novel observations revealed by our study would not have been possible were it not for the single-cell nature of the data. For example, the identification of T-cells with X-chromosome losses and their association with ER- disease, as well as the detection and quantification of pseudo-diploid cells would have been obscured by bulk genomic analysis. Similarly the observation that CNAs can be found at more than two distinct copy number states, which we show is associated with clinical outcome, and the identification of somatic amplicon mosaicism in a substantial proportion of breast cancer biopsies is the result of the single-cell resolution of the data and importantly, has been missed by many prior bulk genomic studies. Thus, the results provide a strong rationale for the continued investment in the development of single-cell genomic technologies (which have lagged behind single-cell transcriptomic technologies) and their utilization in the study of tumor genomes ([@bib8]) to complement bulk sequencing efforts. This will require developing approaches that help in: scaling single-cell genome library construction as well as reducing costs (for example via the implementation of microfluidics) ([@bib32]; [@bib33]), pairing single cell genome with single cell transcriptome information ([@bib23]; [@bib35]), and working with formalin fixed paraffin embedded specimen ([@bib31]; [@bib37]), challenges which many groups have taken efforts to address. Ultimately, single-cell genomic investigations will play an important role in advancing our knowledge of breast cancer genetics and heterogeneity and in the process advance our knowledge of the genetics and biology of the disease and help in its clinical management.

Materials and methods {#s4}
=====================

Patient cohort and tissue samples {#s4-1}
---------------------------------

Tissue samples were collected from 16 patients enrolled on two, neoadjuvant - phase II, open-label clinical trails conducted by the Brown University Oncology Group (BrUOG): BrUOG 211B and BrUOG 211A. Two fresh, pre-treatment core biopsies were obtained per patient, placed into optimal cutting temperature (OCT) and frozen at −80Co for subsequent processing. Patient sample associated metadata (ex: age, ER/PR/HER2 status, among other variables) are provided in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.

RNA-Seq library generation, sequencing and analysis {#s4-2}
---------------------------------------------------

RNA-sequencing libraries we generated and sequenced as previously described ([@bib58]). For sample subtyping, a nearest centroid classifier was implemented using log2 transformed gene expression data aligned on PAM50 list for all BrUOG samples (n = 127) where RNA-seq data was available.

Sample processing and flow cytometry for single-nuclei capture {#s4-3}
--------------------------------------------------------------

Nuclei isolation from frozen cores was achieved by finely mincing frozen tissue, at room temperature, in 1.0 mL of NST-DAPI buffer as previously described ([@bib6]). Prior to sorting, nuclei suspensions were filtered with a 5 mL Falcon round-bottom tube with a cell-trainer cap and kept on wet-ice for a minimum of 30 min. Single-cell sorting was performed using a FACS AriaIIU SORP instrument (BD Biosciences) with the ACDU option (Automated Cell Deposition Unit). DAPI signal was detected by a 355 mM UV laser (450/50 band-pass filter). For tumors with bimodal ploidy distributions (indicative of polyploidy), single-nuclei were sorted from both the diploid and polyploidy distributions for processing. For tumors with only a unimodal diploid distribution, diploid nuclei were sorted and processed. Single-nuclei were deposited into 96-well plates pre-loaded with 9 uL of cell lysis buffer per well as previously described ([@bib6]). All sorted plates were processed on the same day for single-cell genome amplification.

Single-nuclei whole genome amplification and sequencing {#s4-4}
-------------------------------------------------------

Single-nuclei were amplified using WGA4 (Sigma-Aldrich) as per manufacturers protocol. WGA DNA was sonicated to + / - 300 bps using the Covaris instrument (duty cycle −10%, Intensity −4, cycles/burst -- 200 and time 80 s). WGA sonicated DNA (processed in 96 well format, i.e. 96 nuclei per plate) was end-repaired, A-tailed and ligated to 96 custom in-house developed adaptors ([@bib30]). Adaptor ligated products were purified using AMPure XP beads (Beckman Coulter). All adaptor ligated single-cell barcoded libraries (n = 96) were pooled, amplified and quantified for sequencing. All pools were sequenced on the HiSeq instrument using either SR76 or SR101 sequencing.

Single-nuclei CNA analysis of cancer cells {#s4-5}
------------------------------------------

Single-nuclei copy number information was inferred from sequencing data as previously described ([@bib6]; [@bib7]). In brief, sequence reads were mapped to human reference genome (reference hg19), sorted, PCR duplicated removed, and subsequently indexed. Uniquely mapped reads were counted in genomic bins using a previously developed algorithm; Varbin ([@bib41]). Read counts were then normalized and segmentation performed using circular binary segmentation (CBS). To retrieve absolute (integer) copy number information, we utilized an algorithm that assigns ploidy and associated copy number states in single-nuclei data by utilizing a least-squares fitting algorithm used in determining a multiplier value that minimizes the variance from integer copy number states ([@bib7]). All inferred integer copy number values of single-nuclei for all tumors (at bin sizes of \~600 KB, dividing the genome in 5000 bins/5 k) are provided in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. For analysis of fraction (%) of genome sub-clonal, we developed a pipeline where for each genomic bin we counted the number of observable copy number states found in all single-nuclei sequenced from a given patient sample. For a bin to be called sub-clonal, we required the observation of a particular copy number state in any genomic bin in at least 10% of sequenced single-nuclei. Summing all sub-clonal bins and dividing by the total number of bins is used to derive the metric: % genome sub-clonal. For this analysis, the genome was divided into five thousand bins (i.e. bin resolution of \~600 kb). Derivation of breakpoint information was performed as described previously ([@bib2]). In brief, bin positions at which changes in segmented copy number states occur were annotated across all sequenced single-nuclei. To account for the inherent uncertainty in breakpoint bin positioning in segmentation algorithms we utilized a window of 3 bins where a breakpoint in any of those bins was treated as equal (i.e. same breakpoint). Histograms of breakpoint distributions were then constructed and any breakpoint found in less than 90% and more than 10% of all sequenced nuclei from a given tumor sample was deemed sub-clonal. All breakpoints found in over 90% of single-nuclei data were annotated as clonal pins/breakpoints.

Bulk DNA library generation, sequencing and analysis {#s4-6}
----------------------------------------------------

Bulk DNA was purified using phenol-chloroform extraction as previously described ([@bib7]). Bulk DNA was sonicated, end-repaired, A-tailed, and ligated to custom in-house developed adaptors. Libraries were enriched, quantified, and pooled at equimolar concentration for sequencing on the HiSeq instrument. Bulk copy number sequence analysis was performed as described above with the exception that the multiplier, utilized in the least squares-fitting algorithm, was constrained by values derived from flow cytometry data (i.e. ploidy) to achieve absolute copy number values.

T-cell and B-cell sample processing and analysis {#s4-7}
------------------------------------------------

Purified CD8+/CD4+ T-cells and CD19+/CD27+ memory B-cells purified cells were purchased from ALLCELLS (California, USA). Cells were thawed on ice, pelleted, and re-suspended in NST-DAPI buffer for nuclei isolation. Single-nuclei (n = 96) from both sets were sorted from the diploid peak, genome amplified, and processed for multiplex sequencing as described for the cancer biopsies above.

T-cell breakpoint analysis {#s4-8}
--------------------------

The distance between TCR deletions in two nuclei is defined to be the number of bins offset between the left breakpoints plus the number of bins offset between the right breakpoints. In order to normalized for depth and noise, nuclei with at least 1 million mapped reads were each down-sampled to exactly 1 million mapped reads and re-segmented. All T-cell leukemia nuclei share identical breakpoint bin positions. An equal number of T-cell nuclei found in breast cancer tissue with over 1 million uniquely mapped reads included in this analysis were randomly sampled in proportional sets, 1 million times. None of these 1 million random samples had all nuclei sharing identical breakpoints indicating a p-value of \<10^−6^.

DNA-FISH analysis {#s4-9}
-----------------

FISH analysis was performed on frozen section using home-brew Probe. The probe mix consisted of BAC clones containing the full length target gene and labeled with Red, Green, or Orange-dUTP as indicated in in figure legends. DNA was labeled by nick translation using fluorochrome-conjugated dUTPs from Enzo Life Sciences Inc, supplied by Abbott Molecular Inc Tissue processing, hybridization, post-hybridization washing, and fluorescence detection were performed according to standard procedures established at the MSKCC Molecular Cytogenetics Core Facility. Slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped with CoolCube 1 CCD camera controlled by Isis 5.5.10 imaging software (MetaSystems Group Inc, Waltham, MA). Prior to hybridization on tissue section, the probe-mix was hybridized on peripheral blood from normal healthy male to ensure locus specificity. Following hybridization, the tissue was scanned through 63X to assess signal pattern and representative regions imaged (each image was a compressed/merged stack of 12 z-section images taken at 0.5 micron intervals under the Red, Green and Orange filter respectively). Analysis was performed on captured images.

MRI imaging {#s4-10}
-----------

Bilateral breast MRI evaluation with a dedicated breast coil (without compression) was done on a 1.5 Tesla magnet. Images were collected for 6 min at 1 min intervals for following bolus IV gadolinium administration (0.1 mmol/kg). Images were Axial 3D SPGR fat-suppressed T1-weighted. A board certified radiologist interpreted the images.

Bulk copy number analysis of METABRIC datasets for survival analysis {#s4-11}
--------------------------------------------------------------------

We used published copy number data from the METABRIC cohort ([@bib19]) and associated distant relapse free survival data to assess the association between higher dosages of 1q or 8q and patient outcomes. For 1992 cases (from the discovery and validation sets in the initial study), segmented absolute copy number calls were derived using circular binary segmentation. Specifically, the copy number data were smoothed and analyzed with the R package DNAcopy using default parameters, followed by applying the MergeLevels algorithm to the segmented data. In order to remove the dependence between cellularity and the proportion of alterations, we employed different thresholds for calling alterations and high-levels events according to the cellularity of each sample, as previously reported. The clinical outcome analysis included only cases from the original cohort that possessed a 16q loss and either a 1q gain or an 8q gain (446 cases total). Copy number status of the three chromosome arms of interest (1q, 8q, and 16q) was determined by calculating a weighted arithmetic mean of the segments comprising the chromosome arm. In order to allow for parallel analysis of diploid and polyploid tumors, the mean copy number for the 16q chromosome arm (loss of 16q is cytogenetically linked to 1q/8q gain) was used to normalize the degree of gain present in the 1q and 8q arms. For each case, the maximum of the normalized mean copy number from either 1q or 8q was used for downstream analysis. Cases were divided into those with evidence of high-level Gain on 1q or 8q (66 cases, normalized CN \>1.5) and those with low-level Gain (380 cases). Kaplan-Meier analysis was performed to compare these groups within all breast cancer patients using time to distant relapse as the outcome. Since overexpression of the ER and HER2 receptors and lymph node status are strong independent predictors of clinical outcome, we also stratified our findings by ER/HER2 status and lymph node status. In a Cox proportional hazards models that accounts for other clinical covariates (age, grade, size, LN status, ER, PR, and HER2 expression) 1q/8q ratio was not independently significant.

Statistical analysis {#s4-12}
--------------------

All statistical tests were performed using the statistical package R. For the X-loss in T-cells comparison in ER- and ER+ disease a chi-square test was used. For analysis of mutual exclusivity of CCNE1 and VEGFA amplification (copy number higher than 5) in P22, Fisher's Exact Test was used with the alterative hypothesis that true odds ratio is less than 1. For correlations of copy number heterogeneity with biological and clinical variables, Wilcoxon rank order tests were implemented. Spearman rank was used to study the association of tumor size with CNA heterogeneity in ER+ cases. p-values are provided for all statistical tests either in the figures, figure legends, or both.

Sanger sequencing {#s4-13}
-----------------

Normal and cancer single-nuclei WGA DNA (n = 10 for each category) was subjected to PCR amplification of tp53 exons followed by Sanger sequencing. In brief, 50 ng of WGA DNA for 10 nuclei per above category were amplified in a PCR reaction using 1X Amplitaq 360 master mix with 0.2 nM of forward and reverse primers. Resultant PCR products were sequenced using standard Sanger sequencing protocols. A Sanger trace from one representative WGA DNA (one for each normal and cancer) is illustrated in [Figure 5B](#fig5){ref-type="fig"}.

Data and code availability {#s4-14}
--------------------------

Data generated for this study are available thought Short Read Archive (SRA) under BioProject accession number PRJNA555560. All single-cell raw sequencing data were processed using code provided in detailed in [@bib6]. The R Source code for the calculation of % of genome sub-clonal is included as [Source code 1](#scode1){ref-type="supplementary-material"}. The R source code used for the derivation of clonal/sub-clonal pins, as described in Materials and methods section, is available on GitHub at <https://github.com/jysonganan/SCclust/blob/master/R/selectpin.R>.
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Data generated for this study are available thought Short Read Archive (SRA) under BioProject accession number PRJNA555560.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The analysis of breast cancers at the level of Copy Number Alterations to asses intra-tumoral genetic heterogeneity at the level of single-cell sequencing is an important advance, especially because the results translate into a number of interesting new biological observations, for example, X-loss in ER- tumors and pseudo-diploid cells, among others.

**Decision letter after peer review:**

Thank you for submitting your article \"Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jeffrey Settleman as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jonas Demeulemeester (Reviewer \#1); Daniel Rico (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Baslan et al. present an in-depth characterization of intratumor copy number heterogeneity in a cohort of 16 primary breast cancer cases: 4 each of the Luminal A, Luminal B, HER2+ and Basal subtype They also generated bulk RNA-seq and bulk genome sequencing for the same samples. The authors isolate nuclei, sort populations with distinct ploidy using FACS, and perform low-pass whole-genome sequencing on an average 116 cells per tumor. Analyses reveal intriguing patterns of both focal and whole-genome copy number heterogeneity which are likely to have clinical relevance. The previous single-cell genome sequencing study in breast cancer primary tumors only included 2 patients (Navin et al., 2011). Therefore, the new dataset presented is the most comprehensive single cell genome sequencing for breast cancer to date. However, the manuscript was not easy to read as there were many different \"short stories\", which may be difficult to follow for a non-specialized audience. Also, some of the analysis were not clear, which could be improved by making the code and the data available.

Essential revisions:

1\) In the second paragraph of the subsection "CNAs and genetic heterogeneity of stromal, non-cancer cells", the authors describe their breakpoint analysis. At the resolution provided by low-pass whole-genome sequencing, the inferred breakpoints are rough approximations of the true breakends at best. Indeed, authors describe using a window of 3 genomic bins in the Materials and methods. Vice versa, random noise can lead to distinct segmentation in single cells which share a breakend (e.g. the jumps from CN 1 to 2 for the leukaemic cells in Figure 1D). As such, conclusions such as \"indicating unique TCRa recombination events\", \"none of the T-cells shared identical breakpoints\" and \"genetically distinct as judged by the deletion breakpoints at their respective TCRa locus\" should be stated considerably more carefully.

2\) Pseudo-diploid cells are identified in the samples and authors conclude they are not precursors to the main tumor clone based on their distinct CNAs. Authors should further assess whether these cells represent early, potential evolutionary dead-end tumor subclones or do indeed stem from normal breast epithelia. To do this, authors could carefully call SNVs on the pooled low-pass sequencing data and subsequently genotype the called variants in the single cells.

3\) \"High-throughput sequence data should be uploaded before resubmission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)\" The data availability section is not very clear: is it already available, in which case I could not find the related project on SRA (= Short Read Archive, not Short Reach Achieve) nor any link to the data.

4\) The analyses of the data shown on Figure 1D are not sufficiently quantitative. Breakpoints accuracy is inherently limited with shallow coverage sequencing and will correlate with technical aspects, such as number of reads, duplicates, noise in the data, etc. The authors merge breakpoints if in adjacent bins but that these four profiles on Figure 1D visually look different is not enough to persuade readers that biological rather than technical effects are driving the differences. As this is a major claim in the manuscript, the authors are encouraged to make the analyses more quantitative (at least consider the impact of one noise metric related to \"depth of coverage\" in the comparison, as it could be driving the differences between the batches of single nuclei).

5\) Figure 2B: The more single nuclei were sequenced and included in the analyses, the more likely that some events will be considered subclonal (\>=10 nuclei with a different state). Hence, before reaching any conclusions, the authors should explicitly correct the fraction of genome subclonal for this. It looks from other figures that the number of nuclei per cancer sample can vary quite substantially thus potentially influencing the subclonal fraction. As a quick check, an easy way to correct for the number of nuclei analyzed would be for each patient, to downsample to the number of nuclei in the patient with the lowest number.

6\) Figure 5A same remark as Figure 2B applies.

7\) It would be useful to also have the processed data available. I could not see if it is actually included in the SRA BioProject (I guess the accession ID is not yet publicly available) but it would be good to have the patient metadata, the gene expression data, CNA calls of both the bulk and the single-cell samples in supplementary data files and/or in a relevant repository for direct download. As gene expression levels and CNA calls do not contain sequence information, these data should be made available without any restrictions.

8\) The results of different interesting analyses are presented to illustrate the usefulness of the data. However, I had the impression that there were several inconclusive stories: the loss of chromosome X, for example, in connection with BRCA1 and X inactivation is intriguing but it is not further investigated. The authors may want to choose if they want to further invest in making the resource data available for different types of users or choose one of the observations (there are up to nine different conclusions in the Discussion!) to extend further for a more solid and complete \"Research Article\".

9\) Some strong claims are made regarding the association with biological subtypes and patient stratification. For example, the sub-clonality of each tumor is precisely calculated with hundreds of cells per tumor, but at the end of the day there are only 16 patients, just four per sub-group based on gene expression. Indeed, there are some statistical tests that yielded small p-values (e.g. Figures 3C and 5A) but it is unclear what where the unit of analysis -- is the patient the unit of analysis or the cell? The inclusion of the R code used, together with the data, would make the interpretation of these results clearer.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jeffrey Settleman as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Daniel Rico (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The revised version of the in-depth characterisation of breast cancer cases at the level of copy number heterogeneity at the cell level builds an interesting data set, represents an advanced use of the technology and provides information of potential clinical relevance.

Summary:

The revised version of the manuscript has essentially addressed all the key points (i.e. accuracy and level of resolution of the data, cell of origin and linages, and clarification of the narrative and conclusions) but the issues with data and software accessibility have only been partially addressed.

Essential revisions:

For the publication of this article, like for any other one, it is essential that the research community has the ability to the reproduce the reported results. In this case, the metadata associated with the processed data in the supplementary file is missing and the software code to reproduce the various analyses presented is not available. These are significant issues that have to be corrected.
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Author response

> Summary:
>
> Baslan et al. present an in-depth characterization of intratumor copy number heterogeneity in a cohort of 16 primary breast cancer cases: 4 each of the Luminal A, Luminal B, HER2+ and Basal subtype They also generated bulk RNA-seq and bulk genome sequencing for the same samples. The authors isolate nuclei, sort populations with distinct ploidy using FACS, and perform low-pass whole-genome sequencing on an average 116 cells per tumor. Analyses reveal intriguing patterns of both focal and whole-genome copy number heterogeneity which are likely to have clinical relevance. The previous single-cell genome sequencing study in breast cancer primary tumors only included 2 patients (Navin et al., 2011). Therefore, the new dataset presented is the most comprehensive single cell genome sequencing for breast cancer to date. However, the manuscript was not easy to read as there were many different \"short stories\", which may be difficult to follow for a non-specialized audience. Also, some of the analysis were not clear, which could be improved by making the code and the data available.

We thank the reviewers for their positive comments and constructive critique of our work. Below we address the requested Essential revisions.

Regarding the above comment of "the manuscript was not easy to read": we find this perplexing as many colleagues read the work and did not communicate any sort of illegibility pertaining to the text.

Structuring the manuscript in the form of "short stories" was done purposely (and for the benefit of a non-specialized audience) because of the number and diversity of intriguing observations that we noted from the analyses.

Regardless, where we thought it might be off benefit, we have edited certain portions of the text. We hope this makes the text easier to read.

Lastly, we have addressed the unclear analyses referenced above as well as in the Essential Revisions and made all the data publicly available for anyone to download and analyze (the vast majority of the code used in the communicated manuscript is described in our previous referenced works and can be used to reproduce the data). In addition, we are providing all processed single-cell CNA calls for all single-cancer cells analyzed in this study. These are now provided as supplementary data.

> Essential revisions:
>
> 1\) In the second paragraph of the subsection "CNAs and genetic heterogeneity of stromal, non-cancer cells", the authors describe their breakpoint analysis. At the resolution provided by low-pass whole-genome sequencing, the inferred breakpoints are rough approximations of the true breakends at best. Indeed, authors describe using a window of 3 genomic bins in the Materials and methods. Vice versa, random noise can lead to distinct segmentation in single cells which share a breakend (e.g. the jumps from CN 1 to 2 for the leukaemic cells in Figure 1D). As such, conclusions such as \"indicating unique TCRa recombination events\", \"none of the T-cells shared identical breakpoints\" and \"genetically distinct as judged by the deletion breakpoints at their respective TCRa locus\" should be stated considerably more carefully.

Points (1) and (4) of Essential revisions critique the same point: TCR breakpoints and clonal lineage relationship.

Both points are thus collectively addressed here.

We agree with the reviewers that the listed statements above are factually correct:

1\) "the inferred breakpoints are rough approximations of the true breakend at best"

2\) "the analyses of the data shown on Figure 1D are not sufficiently quantitative"

3\) "... consider the impact of one noise metric related to "depth of coverage" in the comparison..."

To address this critique, we have performed the following analyses:

For single T-cell nuclei with at least 1 million uniquely mapped reads derived from: CD8^+^/CD4^+^ purified T-cells, a clonal T-cell leukemia, and T-cells identified in breast tumor tissue (including T-cells exhibiting X-chromosome loss), we:

1\) Uniformly down-sampled uniquely mapped sequencing reads to a coverage of 1 million reads.

2\) Re-segmented the "sequencing-depth normalized" datasets to re-compute the breakpoint positions/boundaries for each single-nuclei.

3\) We then calculated pair-wise distances of the genomic bins that lie within the deletion breakpoints for all single-nuclei of each category.

Low pair-wise distance values indicate a higher probability that the events are clonal due to underlying genetics/biology and not due to technical artifacts. The T-cell leukemia nuclei all shared identical left and right breakpoints.When performing 1 million iterations of random sampling of breakpoint positions (i.e. bins) for the same number of T-cells found in breast tumor biopsies, we find none of these random samples shared identical breakpoints indicating a p-value of \< 10^-6^. This analysis is detailed in the main text, the Materials and methods section, and is illustrated in graphical form in Figure 1---figure supplement 2G.

We have also modified the language in the main text to communicate our conclusions.

It is important to stress that our T-cell breakpoint analysis was not intended to imply that all T-cells found in a tumor mass are TCRa unique and do not share a clonal lineage. This most certainly is not the case and has been reported in the literature. The purpose of the analyses was to corroborate the intriguing finding of X-loss enrichment in T-cells found in ER-negative disease compared to ER-positive disease.

> 2\) Pseudo-diploid cells are identified in the samples and authors conclude they are not precursors to the main tumor clone based on their distinct CNAs. Authors should further assess whether these cells represent early, potential evolutionary dead-end tumor subclones or do indeed stem from normal breast epithelia. To do this, authors could carefully call SNVs on the pooled low-pass sequencing data and subsequently genotype the called variants in the single cells.

We agree that the nature of pseudo-diploid cells in interesting and warrants further investigation, particularly using a combination of SNV and CNA genotyping as pointed out by the reviewers.

Unfortunately, this is not something that is feasible with the datasets we have or the material generated in this study.

1\) We did not perform Whole Exome Sequencing on our tumor biopsies to allow precise genotyping of somatic SNVs in our tumor samples (nor can we now perform the experiment for a multitude of reasons).

2\) The depth at which we performed sequencing of single-nuclei (\~ 2 million reads per nuclei), even when pooling clonal cancer nuclei, let alone pseudo-diploid nuclei, is not sufficient to allow confident, de-novo calling of somatic SNVs.

3\) Even if we attempted to re-sequence normal, pseudo-diploid, and cancer nuclei to higher coverages, the analysis of the data will still be extremely challenging, particularly for rare events such as pseudo-diploid cells, because the WGA method we employed (DOP-PCR) does not provide coverage of the entire genome for each single nuclei WGA DNA material.

All the factors listed above, and others, unfortunately precludes us from performing the requested assessment.

However, the question posed is one of the questions an ongoing study aims to address (a study that is an extension of the work described here). In this ongoing study we have factored this specific subject matter and designed our experimental and analytical protocols to address it.

> 3\) \"High-throughput sequence data should be uploaded before resubmission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)\" The data availability section is not very clear: is it already available, in which case I could not find the related project on SRA (= Short Read Archive, not Short Reach Achieve) nor any link to the data.

We sincerely apologize for this. Our intention was always to make the data publicly available prior to the review of the manuscript. The reason the data was not available (and escaped our knowledge) is because of an apparent corrupted syntax of a subset of the sequencing files that prevented "completion" of the SRA upload and consequently, data release.

All data has now been verified to be released and publicly available.

> 4\) The analyses of the data shown on Figure 1D are not sufficiently quantitative. Breakpoints accuracy is inherently limited with shallow coverage sequencing and will correlate with technical aspects, such as number of reads, duplicates, noise in the data, etc. The authors merge breakpoints if in adjacent bins but that these four profiles on Figure 1D visually look different is not enough to persuade readers that biological rather than technical effects are driving the differences. As this is a major claim in the manuscript, the authors are encouraged to make the analyses more quantitative (at least consider the impact of one noise metric related to \"depth of coverage\" in the comparison, as it could be driving the differences between the batches of single nuclei).

This is addressed above. Please see point 1.

> 5\) Figure 2B: The more single nuclei were sequenced and included in the analyses, the more likely that some events will be considered subclonal (\>=10 nuclei with a different state). Hence, before reaching any conclusions, the authors should explicitly correct the fraction of genome subclonal for this. It looks from other figures that the number of nuclei per cancer sample can vary quite substantially thus potentially influencing the subclonal fraction. As a quick check, an easy way to correct for the number of nuclei analyzed would be for each patient, to downsample to the number of nuclei in the patient with the lowest number.

We thank the reviewers for bringing this issue up and naturally agree with regards to the influence of the \# of single nuclei sequenced and the proportion of the genome found to be sub-clonal. We have done the requested down-sampling analysis above and find no significant differences in the computed fraction of the of the genome found to be sub-clonal for all the tumors with the exception of two (P5 and P58).

Importantly, when performing Wilcoxon rank order testing for statistical associations with discrete and continuous variables, as done in the original submitted work, the change of order of the tumors does not change the statistical significance of the results (i.e. p-values).

Thus, given that the original data (i.e. computed sub-clonal values with all single nuclei factored) represents a more accurate measurement per tumor and that the results following down-sampling normalization do not impact our conclusions, we have kept the stats (and figures) as originally reported.

> 6\) Figure 5A same remark as Figure 2B applies.

Please see point 5 above.

> 7\) It would be useful to also have the processed data available. I could not see if it is actually included in the SRA BioProject (I guess the accession ID is not yet publicly available) but it would be good to have the patient metadata, the gene expression data, CNA calls of both the bulk and the single-cell samples in supplementary data files and/or in a relevant repository for direct download. As gene expression levels and CNA calls do not contain sequence information, these data should be made available without any restrictions.

The critique here is similar to the critique outlined in point 3. In addition, in our revised work we are including all processed, integer copy number calls for all the cancer cells found in the tumor samples analyzed at a bin resolution of 600kb (i.e. diving the genome into 5,000 bins -- 5k).

> 8\) The results of different interesting analyses are presented to illustrate the usefulness of the data. However, I had the impression that there were several inconclusive stories: the loss of chromosome X, for example, in connection with BRCA1 and X inactivation is intriguing but it is not further investigated. The authors may want to choose if they want to further invest in making the resource data available for different types of users or choose one of the observations (there are up to nine different conclusions in the Discussion!) to extend further for a more solid and complete \"Research Article\".

Please see above (3 and 7) regarding data release: all data has been publicly released and is available for download. We are also including all processed data from cancer cells as supplementary data. We feel a strength of our study lies in communicating the usefulness of single-cell genomics in furthering an understanding of cancer -- which is pointed out in the text. This is very important since single-cell genomics in reality has not progressed sufficiently enough in comparison to single-cell transcriptomics (due to many reasons).

Thus, one of the aims of our manuscript was to communicate the importance of single-cell genomics that would entice the research community to adopt single-cell genomics.

We feel the importance of single cell genomics was sufficiently communicated in our work by illustrating the panoply of novel genetics observations that where gleaned from the data as a whole rather than focusing on one particular observation.

Thus, it is our opinion that communicating a plethora of novel findings, and emphasizing the power of single-cell genomics in retrieving those findings, we are communicating a "complete Research Article".

Regarding the comment about the interesting link BRCA1 and X-chromosome loss in T-cells: we agree with the reviewer. This is something we hope to further address in ongoing studies (please see point 2 above).

> 9\) Some strong claims are made regarding the association with biological subtypes and patient stratification. For example, the sub-clonality of each tumor is precisely calculated with hundreds of cells per tumor, but at the end of the day there are only 16 patients, just four per sub-group based on gene expression. Indeed, there are some statistical tests that yielded small p-values (e.g. Figures 3C and 5A) but it is unclear what where the unit of analysis -- is the patient the unit of analysis or the cell? The inclusion of the R code used, together with the data, would make the interpretation of these results clearer.

We are not entirely certain what is meant by "strong" claims. If by "strong claims" the reviewers mean "exaggeration", we respectfully disagree.

To illustrate, regarding the association of CNA heterogeneity with molecular and clinical parameter (i.e. biological subtypes and patient stratification), in the Discussion section we explicitly state "the association of CNA heterogeneity with parameters such as polyploidy and ER- status provides *an indirect association* of heterogeneity with clinical parameters".

"Indirect association" cannot be construed as a "strong" claim in our opinion.

Similarly, we explicitly state "we see *somewhat* of an inverse correlation between tumor size and CNA heterogeneity". "Somewhat" does not communicate a "strong claim" either.

We are simply laying out all the observations we have been able to glean from the data in an effort to illustrate:

1\) The magnitude of CNA heterogeneity in breast cancer and hypothesize about its effect on the biology of tumors.

2\) The importance of single-cell genomics in studying cancer.

Regarding the p-values and the unit of the analysis comment above:

We believe it is clear that for Figure 3C, the unit is a single-cell since we are describing a single tumor.

Similarly for Figure 5A, the unit is the patient since we are discussing the tumor cohort.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Essential revisions:
>
> For the publication of this article, like for any other one, it is essential that the research community has the ability to the reproduce the reported results. In this case, the metadata associated with the processed data in the supplementary file is missing and the software code to reproduce the various analyses presented is not available. These are significant issues that have to be corrected.

The metadata on all tumor samples analyzed is now included in the revised version (Figure 1---source data 1). The software code to process the sequencing data (i.e. derive integer copy number state) has been described in detail in the literature and is appropriately cited. The source code for deriving two metrics used in statistical associations: (1) % genome sub-clonal and (2) clonal/subclonal pins/breakpoints, are now included as a supplementary file and a URL, respectively.

[^1]: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, United States.

[^2]: National Institutes of Health, Bethesda, United States.

[^3]: USC Dana and David Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, United States.
